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Abstract: An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic.
However, despite significant efforts to develop a safe and effective vaccine, the modestly protective
RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition.
This review will outline the history of HIV vaccine development, novel technologies being applied
to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our
understanding of vaccine-induced immune correlates of protection.
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1. Introduction
The lentiviral retrovirus, Human Immunodeficiency Virus type 1 (HIV-1), is the etiological agent
behind the global Acquired Immunodeficiency Syndrome (AIDS) epidemic. Since the AIDS epidemic
was first identified in the early 1980s, approximately 70 million individuals have become infected,
resulting in 35 million deaths. The introduction of combination antiretroviral therapy (cART) has
dramatically altered the epidemic landscape and has been responsible for the 48% decline in AIDS
related deaths between 2005 and 2016 [1]. Despite this remarkable achievement, in 2016 it is estimated
36.7 million individuals are now living with HIV and approximately 800,000–1.2 million people died
due to AIDS-related deaths. Owing to comparative phylogenetic analysis, the origins of the HIV
epidemic are believed to be zoonotic transmission events occurring between select strains of wild
chimpanzee simian immunodeficiency virus (SIV) crossing over into human populations [2]. Currently
it is understood that this zoonosis might have happened on as many as 4 independent occasions,
giving rise to the four classifications of HIV, groups N, O, P, and the pandemic M group [3,4].
HIV-1 is primarily a sexually transmitted virus with transmission occurring through mucosal
surfaces. Less frequently, HIV can also be spread vertically by mother-to-child exposure and by direct
intravenous inoculation. HIV infection results in the progressive depletion of CD4 T cells, the very
cells that orchestrate the critically protective adaptive immune responses to pathogenic infections,
until such time as the immune constitution is severely eroded and opportunistic infections ensue.
While CD4 T cells serve as the primary targets for HIV infection and replication, not all CD4 T cells
are equally depleted. For instance, activated CD4 T cells are more susceptible to productive infection
than their naïve counterparts [5]. Initially it was assumed HIV-mediated CD4 T cell depletion was
occurring directly via viral cytopathic effects [6]; however, other studies suggested the cells dying in
lymph nodes in response to infection were uninfected bystander cells [7]. More recently, a form of cell
suicide mediated by caspase-1 dependent pyroptosis was attributed to the massive decline in CD4 T
cells [8]. Pyroptosis occurs in non-permissive CD4 T cells (~95% of cells), where infection leads to the
accumulation of incomplete reverse transcripts that are detected by endogenous DNA sensor IFI16,
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leading to inflammasome assembly [8], with the end result being caspase-1 activation and the death of
abortively infected cells. This contrasts with permissive CD4 T cells (~5% of cells), in which infection
causes the productively infected cell to undergo caspase-3 mediated apoptosis [8]. While pyroptosis
is readily detected within infected lymph nodes, it is not seen in peripheral blood T cells, probably
due to their lower activation status compared to lymph node CD4 T cells [9]. In fact, the frequency
at which and the extent to which HIV viral replication occurs in lymph nodes is between ~5–10-fold
higher than in peripheral blood [10].
During the very early events post exposure, the HIV viral quasi-species experiences multiple
genetic bottlenecks before going on to establish a systemic infection. This dramatic contraction
in viral diversity between the sequences identifiable in the donor’s genital secretions, the vaginal
mucosa of the recipient, and the systemic compartment is due to a combination of physical and
immunological constraints on the virus. The result is a single viral variant establishing systemic
infection in >75% of individuals, with multiple variants (<5) involved in >20% of infections [11,12].
Evidence from non-human primate (NHP) studies using atraumatic inoculation of high doses of
SIV has provided a blue print for the critical early events during transmission. From such studies,
we now know the virus can cross the mucosal epithelium within hours and establish a founder
population of infected cells [13]. These founder populations rapidly expand and evolve into larger
foci of infection over the next few days, and within the first week the virus spreads to the local
draining lymph nodes and becomes a self-propagating infection. During vaginal transmission, vaginal
epithelial Langerhans cells (LCs) and dendritic cells (DCs) were identified as the major viral targets
for initial infection [13–15], while contradicting studies suggested T cells were the key targets for
early infection [16,17]. Due to their anatomical locations within mucosal tissues, CD1a+LCs and DCs
are perfectly situated to encounter invading pathogens quickly [18]. While the migratory properties
of antigen-loaded LCs are still being evaluated and appear to depend on the presence/absence of
stromal cells and TGF-β secretion [18,19], certain stromal DC subsets encountering HIV can capture
and transport virus to the local draining lymph nodes. The main DC population resident within the
female reproductive tract (FRT), the CD11chiCD11b+CD14+ cells co-expressing CD1c, is suggested as
important for HIV capture and transport to local draining lymph nodes [20].
Through the use of the NHP SIV infection model and phenotyping of infected cells, it has
become clear that the early cellular targets for infection are CCR6+ CD4+ T cells, which expressed
the RORγT transcriptional regulator [21], demonstrating that the initial targets for infection were
mucosal Th17 cells [21]. Interestingly, although the vagina had the greatest number of virally infected
cells, multiple foci of infections were established throughout the reproductive tract, challenging
earlier assumptions that the transformation zone and endocervix is the site for viral transmission and
infection [17,21,22]. Thereafter, infection spreads systemically via the thoracic duct to various organs
of the body including other secondary lymphoid tissues, brain, liver, lungs, and gut [23]. Studies on
antiretroviral therapy (ART)-treated NHPs infected intrarectally with SIVmac251 have shown that
the latent, replication-competent proviral reservoir is established within the first 3 days of infection
(i.e., the eclipse phase) before virus is detectable. This is substantially earlier than previously thought
and suggests that a viable preventative vaccine has a very narrow window of opportunity within
which to either prevent or contain infection before a pool of latent virus is established [24].
2. Immune Response to HIV Infection
Once HIV establishes infection, a strong host-mediated immune response is mounted. This initial
response is ultimately unable to contain viral replication. As mentioned previously, in the majority of
cases, only a single transmitted/founder (T/F) virus is responsible for disseminating infection. In these
early stages of infection, the virus effectively enters an evolutionary arms race with the counteracting
immune response, driving viral diversity and immune escape. Shortly after infection (~10–15 days),
the virus reaches a peak viral load before declining to a viral set point (~30 days), a prognostic marker in
the AIDS timeline. This decline in peak viremia coincides with a rapid amplification in anti-viral CD8 T
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cells, which places a downward selective pressure on the virus [25]. Despite the cytotoxic T lymphocyte
(CTL) pressure, HIV evades CD8 T cell control of viremia by rapidly evolving susceptible T cell target
epitopes via mutations that affect epitope-HLA binding, mutations that interfere with intracellular
epitope processing or mutations that prevent T cell receptor (TCR)-epitope-HLA recognition. This viral
evolution acts in concert with Nef-mediated downregulation of polymorphic HLA-A, B, and C
molecules on infected CD4 T cells, thereby reducing recognition of infected target cells. Within 6–7
days post-infection, a burst in B cell plasmablast (low affinity short-lived extrafollicular plasma cells
with minimal Ig-variable region diversification) numbers occurs, comprising as much as 13% of the
circulating B cells in the blood, of which less than only 1.5% has been reported to be HIV-specific [26].
This contrasts with other viral infections like dengue and RSV, in which plasmablast numbers
can constitute as much as 30% of the peripheral lymphocyte population, with the majority being
virus-specific, strongly indicating that significant indirect B cell activation occurs during early HIV
infection [26].
Production of plasmablasts signals the introduction of HIV-1 virions or viral antigens into
secondary lymphoid structures. Lymph nodes are characterized by the presence of follicles containing
IgM+IgD+ B cells that are separated by an interfollicular region. The T cell zone, containing an
abundance of T cells, strategically borders the B cell follicle. During adaptive immune responses,
germinal centers form within the B cell follicle, which contains a follicular dendritic cell network (FDC)
at its centre [27]. Early after infection, infectious viral particles can be located on the surface of FDCs in
the form of long-lived immune complexes. Although FDCs are not known to be productively infected,
they are believed to present infectious virus to CD4 T cells that is in close proximity. T follicular
helper cells (Tfh) also reside within lymph nodes, a subset of CD4 T cells that is tactically positioned
to provide the necessary help to resident B cells and a cell type regarded as a major HIV reservoir.
Generally speaking, exogenous antigenic interactions with the B cell receptor (BCR) on the B cell
surface result in BCR cross linking, antigen internalization, processing, and presentation in the context
of MHC class II. This results in the activation of the naive B cell, which then migrates to the T and B cell
zone border for interactions with T cells and to become fully activated [27]. The Tfh cells provide the
necessary cognate interactions (CD40-CD40L, MHCII-peptide-TCR) and secreted soluble mediators
(e.g., IL-4 + IL-21 cytokines) at the interface between the T and B cell zones [28], the consequences of
which are B cell clonal expansion, differentiation, and Ig class switching. Additional co-stimulatory
interaction through ICOS and activation of SLAM is important and gives rise to either low affinity
plasmablasts, which mature into memory B cells, or it continues to proliferate within the follicle and
generate germinal centres [28]. Tfh cells are critically important for the generation of high-affinity GC
B cells and to promote the back and forth interzonal migration of B cells for repeated rounds of somatic
hypermutation (SHM) [27]. Interestingly, Tfh cell accumulation in germinal centers of secondary
lymphoid tissues has been correlated with hypergammaglobulinemia and activated germinal center
B cells, with the frequency of Tfh cells secreting IL-21 and IL-4 correlating with the development of
broadly neutralizing antibody (bnAb) production [29,30].
The early antibody responses do not neutralize the infecting virus, are initially polyreactive,
and are directed towards the gp41 glycoprotein before anti-gp120 antibodies are raised [31,32].
Interestingly, priming of anti-gp41 B cell response has been shown to occur in the intestine and
in response to intestinal microbiome exposure [33]. This microbiome-gp41 cross-reactive priming
may be behind the early gp41 dominated antibody response in early HIV infection [33]. Mucosal
antibodies are often referred to as the front lines of immunological defense against pathogens exploiting
mucosal surfaces as portals of entry to the body. For this reason, their elicitation through infection
or vaccination can be important to ameliorate disease or prevent infection. Within mucosal fluids,
IgG, IgM, and IgA antibodies are found, with the latter two isotypes existing as both monomeric and
polymeric forms. While the protective properties of mucosal IgA in the context of HIV-1 infection
or acquisition prevention have not been proven, elicitation of anti-viral IgA against a number of
disease-causing organisms has been shown to augment or correlate with protection. This includes
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vaccinations against influenza, polio, and rotavirus [34]. Certainly, tantalizing evidence from highly
exposed, persistently seronegative individuals (HEPS) suggests that HIV-specific IgA responses
correlated with resistance to HIV acquisition [35]. As such, it is widely anticipated that local anti-HIV
IgA responses could play a significant role in protection against HIV infection, if present in mucosal
secretions prior to transmission. As discussed previously, the early antibody response is directed
towards the gp41 portion of Env with the plasma anti-gp41 IgA response being detectable (~13.5 days)
before any anti-Gag IgA antibodies (~25.5 days) [34]. Interestingly, during this acute stage of infection,
the anti-gp41 IgA response in plasma can be detected during Fiebig stage I/II in 25% of individuals,
which then climbs to 50% of individuals by Fiebig stage III. This contrasts with the delayed appearance
of anti-gp41 IgA in mucosal samples, which is normally only detectable in ~33% of individuals in
Fiebig stage IV [34]. Why such a delay in the appearance of IgA occurs in mucosal secretions is
currently unknown. In addition to a delay in the appearance of IgA in mucosal secretions, anti-gp41
IgA antibodies in mucosal secretions have been shown to have a relatively short half-life (~2.7 days)
when compared to plasma anti-gp41 IgA (~48.2 days) [34], raising questions as to how to extend
the residency of IgA in mucosal secretions when elicited through vaccination. Finally, the early
g41-specific IgG response can be found at much higher concentrations (11-fold higher) in genital
secretions compared to gp41-speific IgA.
Although HIV infection is associated with B cell dysfunction and a blunted antibody response,
during early infection autologous strain-specific neutralizing antibodies to the T/F virus and its
evolving variants arise within 3–12 months post infection (Figure 1) [36,37]. The generation of B
cell lineages producing autologous neutralizing antibody responses forces viral evolution to escape
the antibody mediated immune pressure. Ultimately, after a number of years of this continued
viral evolution and diversification in response to the relentlessly pursuing B cell immune response,
development of bnAbs in ~20–50% of HIV+ individuals can occur [38–41]. Within individuals
generating bnAbs, more than 1 lineage of B cell can be involved, widening the potential of
neutralization breadth of the antibody response [42,43]. Despite the generation of circulating bnAbs in
certain individuals, their presence is not associated with control of viremia in vivo. However, passive
infusion studies in NHPs have clearly demonstrated a protective role for bnAbs against challenge
infections [44–49]. Why all HIV infected individuals make autologous neutralizing antibodies against
the infecting viruses, but less than 50% of HIV+ individuals go on to make any level of bnAb response,
is unknown. One reason behind the failure of vaccines to recapture what is seen in natural HIV infection
is that host control mechanisms may disfavor bnAb production due to potential antigenic mimicry
and autoimmunity. Certainly, many bnAbs have been shown to bind to human proteins or have been
identified by diagnostic assays used for determination of autoimmune disease [50–53]. In addition to
autoreactivity, it is well known that bnAbs have extensive levels of SHM and/or long heavy chain
complementarity determining region 3 (HCDR3) loops, characteristics of B cells that would normally
be eliminated by central and peripheral tolerance [54,55]. What is clear is that bnAb lineages display
extraordinary levels of mutations. Under normal circumstances, somatic hypermutation (SHM) and B
cell selection enable rapid, high affinity antibody production in a matter of weeks [56]. This involves a
small number of variable region mutations in the developing antibody, which can diverge by as much
as 5% from the germline sequences. This is in stark contrast to certain bnAbs, in which in excess of
30% of variable region nucleotides can be exchanged [56]. Analysis of VRC01 lineage evolution over a
15-year period identified a rapid rate of bnAb evolution to an early autologous gp120 molecule, which
slowed down over time. Despite this deceleration in the mutation rate, antibody evolution appears to
continue in response to chronic persistence of antigen, thereby enabling continued SHM [56]. How
such extended levels of antigen persistence and B cell evolution can be achieved in the context of
prophylactic HIV-1 vaccines remains to be seen.
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Figure 1. The HIV-1 mucosal transmission bottle neck and developing antibody response. Early after
exposure, transmitted founder (T/F) viruses cross from the external mucosal lumen into the mucosal
stroma and establish a foci of infection. Within a period of hours to days, the virus then migrates
to local draining lymph nodes as either free virus or is carried there by migrating dendritic cells.
Within the lymph node, there is an abundance of CD4 target cells to propagate infection, resulting
in exponential viral amplification and systemic spread. During these initial few days and weeks,
the infecting virus is clonal in nature with little genetic diversification. The early humoral immune
response is characterized by the initial development of anti-gp41 antibodies before anti-gp120 are
detectable. Over the next few weeks and months, the virus enters into an evolutionary arms race with
the developing B cell response, resulting in genetic diversification of the transmitted founder into a
viral quasi-species. These viral escape mutants help drive the anti-HIV B cell response and ultimately
give rise to autologous neutralizing antibody responses and then to broadly neutralizing antibody
responses within a subset of these infected individuals.
3. Previous HIV-1 Vaccine Efficacy Trials
Since 1987, hundreds of vaccine candidates have been clinically tested as HIV-1 vaccines. However,
to date only six HIV-1 vaccine efficacy trials have been completed (Table 1). Most vaccines work
through elicitation of protective antibody responses. Furthermore, in a number of disease states,
vaccine conveyed immunity has been shown to correlate with both induction and the magnitude
of the vaccine elicited antibody titre. Therefore, in the 1990s, initial vaccine candidates were based
on Env glycoproteins and tested in preclinical NHP studies [57–59], as well as in human safety
and immunogenicity trials [60–64]. Such studies provided critical evidence that Env-based vaccines
could be safely administered and were immunogenic in humans and NHPs. Yet, studies in NHPs
soon identified a significant flaw in early recombinant Env vaccines. Although the elicited immune
responses were protective against homologous challenge infections, they were not protective against
heterologous challenge [65,66]. In 1999, the randomized, double blind, placebo-controlled efficacy
trial of AIDSVAX B/E (VAX003) was initiated and involved the enrollment of 2546 injection drug user
(IDU) cohort in Thailand. The AIDSVAX B/E vaccine contained two recombinant gp120 HIV Env
antigens from a CXCR4 lab-adapted clade B strain and a CCR5 primary subtype CRF01_AE isolate
adjuvanted in alum [67]. Despite induction of anti-gp120 antibodies, VAX003 did not provide any
protection from infection, with 8.3% in the placebo and 8.4% in the vaccine arm becoming infected [67].
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In VAX003, vaccine efficacy was estimated at 0.1%. Another Env-based efficacy trial named VAX004
was a randomized, double blind, test of AIDSVAX B/B. This formulation was the first phase 3,
placebo-controlled efficacy study against HIV acquisition and contained subtype B recombinant gp120
in alum. VAX004 was administered to 5403 men who have sex with men (MSM) and women at high
risk of infection in North America and the Netherlands [68]. Despite inducing neutralizing and CD4
blocking antibody in all vaccines, HIV seroconversion rates were 6.7% in the vaccine arm and 7% in the
placebo arm, with overall vaccine efficacy estimated at 6% [68]. In short, despite being immunogenic,
VAX003 and VAX004 recombinant Env-based vaccines failed to demonstrate any level of protection
from infection.
Table 1. Previous HIV-1 vaccine efficacy trials.
Trial ID Vaccine Description Phase Number ofParticipants Year Results
AIDSVAX B/E
(VAX003)
Two clade B and one
CRF01_AE gp120
antigens in alum
III 2546 1999.3–2003 No protection
AIDSVAX B/B
(VAX004)
Clade B recombinant
gp120 antigens in alum III 5417 1998.6–2003 No protection
HVTN502
(STEP)
MRKAd5 HIV-1
Gag/Pol/Nef IIb 3000 2004.12–2007.9
Halted at interim analysis
for futility; early transient
increased infection
in vaccinees
HVTN503
(Phambili)
MRKAd5 clade B
Gag/Pol/Nef IIb 801 2007.1–2007.9
No effect, late increased
HIV infection in
unblinded male vaccinees
RV144
ALVAC-HIV vCP1521,
AIDSVAX B/E rgp120
in alum
III 16,402 2003.10–2006.7 31.2% protection
HVTN505 DNA, rAd5 (A, B, C) IIb 2504 2009.6–2017.8 No protection
The previously completed human efficacy trials designed to prevent HIV acquisition are shown. Ad = Adenovirus;
gp = glycoprotein; HVTN = HIV Vaccine Trials Network; MRK = Merck; MVA = modified vaccinia virus Ankara;
NCT = National Clinical Trials identifier; vCP = canarypox vector; CRF = circulating recombinant form.
In contrast to the previous disappointing Env-based efficacy trials, the STEP (HIV Vaccine Trials
Network 502, HVTN502) and Phambili (HVTN503) trials were designed to elicit cellular immune
responses. This was done as a considerable body of research was being generated; suggested cell
mediated immunity was important in the control of both HIV replication and disease progression in
long term non-progressors [69–71]. This body of evidence was also supported from NHP challenge
models [72–74]. The STEP study was a phase II, double-blind, randomized, placebo-controlled trial
using the MRKAd5 HIV-1 Gag/Pol/Nef vaccine in high-risk of infection, HIV-1 seronegative women
and MSM [75]. This multicenter trial enrolled 3000 individuals with study sites in North America, the
Caribbean, South America, and Australia [75]. The closely related phase II Phambili trial involved
MRKAd5 clade B Gag/Pol/Nef administered to 801 of a scheduled 3000 heterosexual men and women
in South Africa [76]. Although both vaccines were immunogenic and well tolerated, an exploratory
multivariate interim analysis from the STEP trial revealed an alarming increased incidence of HIV-1
acquisition in male vaccinees versus placebo recipients who had adenoviral seropositivity (5.1% vs.
1.4% per year, respectively) or were uncircumcised (5.2% vs. 1.4% per year, respectively). On the
basis of this negative news, both trials were stopped. Interestingly, a follow up sieve analysis was
performed on HIV-1 genome sequences from 68 newly infected volunteers from the STEP trial to
evaluate if the vaccine exerted any selective pressure on breakthrough viruses. Indeed, a genetic
imprint was identified on the founder viral strains. The sieve effect was only seen in predicted epitopes
and only in proteins that were components of the vaccine, indicating the possibility of T cell pressure
post-infection [77]. Therefore, despite the failure to protect and being stopped early, the STEP trial
MRKAd5 HIV-1 Gag/Pol/Nef vaccine was the first to place a selective pressure on the infecting virus.
In 2009, the results from a randomized, multicenter, placebo-controlled efficacy trial involving
recombinant canarypox vector (ALVAC-HIV) plus two recombinant gp120 boosts (AIDSVAX B/E)
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were released [78]. The RV144 “Thai Trial” enrolled 16,402 healthy individuals at heterosexual risk of
HIV acquisition, who were divided into vaccine and placebo arms. In the intention-to-treat analysis,
a trend towards prevention of HIV-1 infection among vaccine was seen (vaccine efficacy = 26.4%).
However, in the modified intention-to-treat protocol, in which seven individuals were removed from
the study for being HIV+ at initiation of the study, vaccine efficacy rose to 31.2% [78]. Interestingly,
a post hoc analysis in behavioral risk and vaccine efficacy revealed an early peak in vaccine efficacy
estimated to be 60.5% in the first year, which declined to 31.2% thereafter [79]. Protection in this study
was attributed to development of non-neutralizing IgG against the V1/V2 region of HIV-1 Env and not
the low-level induction of neutralizing antibody. Comparing the genetic sequences of breakthrough
viruses in vaccine recipients by sieve analysis identified that HIV strains isolated from vaccinees had
genetic signatures of vaccine-induced immune pressure within V1/V2 [80]. The escape depended
on class I HLA A*02 and A*11 restricted epitopes in the recombinant gp120, with vaccine efficacy
greater in A*02+ (54%) individuals than A*02− (3%) individuals [80]. Within A*02+ individuals,
vaccine efficacy of breakthrough viruses containing K169 within V1/V2 was 74% compared to A*02−
with 15%, thereby emphasizing that HLA A*02 may have played a significant role in RV144 and the
overall importance of HLA genotypes in HIV vaccine trials [80]. Finally, the V2 binding antibody from
vaccines was able to mediate ADCC activity, and this was dependent on K169 in the breakthrough
Envs [81].
More recently, the randomized, double-blind, placebo-controlled efficacy trial (HVTN505) of the
Vaccine Research Centre’s (VRC’s) DNA/Ad5 HIV-1 vaccine was halted by recommendations from
the data and safety monitoring board for lack of efficacy. The trial enrolled 2504 men and transgender
women who have sex with men to receive either vaccine (n = 1253) or placebo (n = 1251) [82]. In this
study, the baseline Ad5 serum neutralizing antibody titre was to be less than 1:18, and men had to
be circumcised. The DNA vaccine contained clade B gag/pol/nef and clade A, B, and C env while the
recombinant Ad5 expressed clade B gag-pol and clade A, B, and C env. HIV acquisition was detected in
27 vaccinees at week 28+, while only 21 infections were recorded in the placebo arm (vaccine efficacy
= −25%) [82]. Overall, 41 individuals became HIV+ in the vaccine arm, while 31 became infected in
the placebo arm, supporting a lack of vaccine efficacy [82]. Despite an increase in HIV infection in
the vaccine arm vs. placebo, the number of infection in the week 28+ primary analysis and the total
number of infections in the modified-intention-to-treat analysis revealed no statistical significance [82].
Subsequent analysis of breakthrough viral genomes in vaccinees vs. placebo recipients revealed that
HIV-1 diversity was significantly lower in gag, pol, vif, and env genes, with Env sequences significantly
more distant from the subtype B vaccine insert in vaccines [83]. Interestingly, these signatures of
immune pressure were mapped to the CD4bs [83]. Since the sieve analysis was identified primarily
in Env, it is argued that the selective pressure on breakthrough virus in vaccinees was in Env regions
associated with infectivity, with indications that antibodies might be partially responsible. Taken
together, this suggests that although no protection from HIV acquisition was seen (i.e., no vaccine
efficacy), the vaccine might have induced a rapid Env diversification post-HIV acquisition due to
elicited immune pressure, or the vaccine did protect against HIV acquisition from strains that were
more closely related the vaccine strains [83].
In summary, of the six HIV-1 vaccine efficacy trials that have been carried out, only the RV144
study has demonstrated a modest reduction in HIV-1 infection rates using a modified intention to treat
protocol. Post Hoc analyses on the STEP and HVTN505 trials revealed enhanced viral evolution in
response to vaccination, suggesting immune pressure was being exerted on the virus. Collectively,
a great wealth of information has been accrued from these studies, with vaccines based on just viral
vectors or heterologous viral vector prime protein-boost protocols appearing to perform better than
multi-dose protein-based vaccines. A rich HIV-1 vaccine clinical trials pipeline, along with the initiation
of HVTN702, a repeat of the RV144 trial in South Africa, provides much hope that additional correlates
of protection will be elucidated and that an HIV-1 vaccine might yet become a reality.
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4. Preclinical Evaluation of Novel Protein Based Immunogens
Shortly after establishing that the HIV retrovirus was the cause of AIDS, the field was wildly
optimistic that a vaccine would be quickly and easily found to either prevent or alter the disease
course, a promise that has not yet been fulfilled. After some very early work in the newly established
non-human primate models that used various nef or multiple gene deleted viral strains, it was clear
that the live-attenuated vaccine strategy was unlikely to produce an acceptable vaccine, as the virus
demonstrated great powers of deletion repair and enhancement of viral fitness [84–86]. Next, vaccine
development studies concentrated on creating a subunit vaccine, a strategy that was considered to
have major advantages in terms of potential safety profile over the more traditional live-attenuated or
even a heat-killed whole virus vaccine. Work focused on producing recombinant proteins of various
Env gp160 or gp120 versions from various viral strains and clades, as well as the assessment of the
immunogenicity of such proteins produced from a multitude of gene expression (mainly viral) systems.
Indeed, pre-clinical studies have examined the potential of countless permutations of vaccination
regimens consisting of expression vectors, recombinant proteins, and delivery schedules, as well
as delivery methods and routes. These pre-clinical studies fed through to clinical trials, and it has
become increasingly clear that while it is relatively straightforward to elicit appreciable immune
responses in people, the immunity generated by the first or second generation vaccine proteins is
not protective and lacks neutralization breadth. What has also become clearer over the intervening
years is that a relatively large percentage (10–30%) of infected people are able to produce bNabs and,
indeed, about 1% will go on to naturally produce antibodies that are extremely broad and that are
highly potent, and are effective at very low serum levels [87,88]. Therefore, the natural experiment has
been performed; people can make potent and broadly neutralizing antibodies, which is particularly
impressive, as these are generated in the setting of infection and a potentially waning immune system.
These observations have pushed the field of vaccinology to focus on antigen design to produce
proteins that most accurately reflect the native HIV Env trimer and also to target the pathway of bNab
development from the early reactive germline sequences to the final hypermutated bNab clones.
The Env protein present on a viral particle can exhibit a number of structural forms, whether
due to the conformational movements typical of all protein complexes or the various intermediates
caused by co-receptor binding and the fusion of the viral Env to the cellular receptor, or from the
overall metastability of the trimeric protein complex. In addition, the viral particle ages the surface
glycoproteins, which undergo degradation by proteases, in which even a small break in the protein
chains can lead to a dramatic loosening of the integrity of the trimer, in which torsional forces in the
Env structure distort the molecule presenting a large (currently undefined) number of Env structure
variants to the humoral immune system [89].
This heterogeneity of potential Env immunogens pushed the field to accelerate the design and
development of stable HIV-1 Env trimers that are soluble and have a native trimer tertiary and
quaternary structure. These designer Envs incorporated a number of stabilizing mutations and
cross-linkages that forced the protein into a native-like shape, mostly retaining the glycan moieties
but essentially locking the Env into a stable non-infectious trimer (Figure 2). The primary exemplar
of the optimal native-like trimer to date is the BG505 SOSIP.664 molecule, although this recombinant
molecule has recently been shown to possess an unusual ‘glycan hole’ shared by only 3% of global
isolates, allowing access of bnAbs to the native-like structure [90]. These glycan holes are present in
many HIV Env isolates, at various glycosylation sites, and are potential weaknesses to target in the Env
glycan shield. However, while it is apparent that many designed Env trimers, as well as Env isolates,
have these alterations in the glycosylation residues to create holes in the ‘glycan shield’ that allow the
generation of neutralising tier 2-type antibodies, it has been observed that these Env generate sera
with reasonable autologous potency but little heterologous or breadth of activity. Therefore, while
these designed Env are clearly highly native and demonstrate strong structural integrity, they have not
yet been able to elicit bnAbs of the type that can be isolated form infected patients.
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Figure 2. Structural models of the BG505.SOSIP.664 HIV Env protein. The HIV-1 BG505.SOSIP.664
protein PDB data file (PDB file 4ZMJ: Crystal Structure of Ligand-Free BG505 SOSIP.664 HIV-1 Env
Trimer [91,92]) was imported to UCSF Chimera program [93] to visualize the molecular structure.
The hydrophobicity model on the left (looking at the protein from the top) shows the typical
propeller-shape of the BG505.SOSIP.664 HIV Env trimeric molecule, while the ribbon diagram on
the right gives detail of the positions of the beta-pleated sheets, alpha-helices and loops that make the
structure. The BG505.SOSIP.664 HIV Env exhibits a mature and pre-fusion closed trimer, a conformation
recognised by bnAbs that would be expected to target the native trimer presented on infectious HIV.
Further design modifications of the BG505 molecule and other Envs have increasingly succeeded
in creating stabilised and more native-like trimer structures that are likely to be the next generation
vaccine candidates to generate bnAbs.
Of the six well described broadly neutralising Ab clusters in the trimer HIV Env molecule, three
are highly dependent on the quaternary structure of the Env and also have a strong bias for binding to
both protein and glycan elements of the Env structure. Depending upon the final trimer quaternary
conformation, there can be more or less exposure of glycan moieties leading to higher or lower degrees
of glycan processing, and therefore the final protein-glycan complex can appear strikingly different to a
potentially reactive B cell from just a small relaxation or tightening of the overall trimer. Indeed, some
50% of the mass of the HIV Env trimer are glycans, most of which are of the incompletely processed
high-mannose type, indicating that the constrained structure of the trimer complex is protecting these
glycans from being processed into complex sugars during golgi transit.
Rational vaccine antigen design has been informed by the isolation of a number of bnAbs against
the HIV Env protein; these naturally occurring antibodies are effectively telling us what we need
to make, and, of course, each one of these antibodies contains a ‘negative imprint’ of a part of the
Env molecule and the tertiary structure of that epitope. It is clear that the continued isolation and
analysis of these bnAbs will further advance our knowledge of the antigen–glycan structures required
that match the final matured and somatically hypermutated bnAb clone, but these observations
will not necessarily inform us as to how the bnAb clone developed. The heavy and light chain
variable domain (VH and VL) family usage of a bnAb will tell us the preferential antibody (Ab) gene
family usage of the germline ancestor. However, for HIV it has been shown that most germline
ancestors do not in fact bind to HIV Env [94] and have undergone a high degree of somatic mutations,
insertions, or deletions, though logically the germline progenitor must have bound to one of the
versions of HIV Env to have been initially selected [38,95–97]. Furthermore, a vaccine antigen that may
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effectively stimulate a bnAb germline precursor may be quite different from an Env carefully designed
to replicate the native-like and infectious trimer, and thus an effective vaccine regimen may require
multiple designed immunogens (native-like or not) to drive bnAb development and maturation [98].
Recent work utilizing germline reverted bnAbs to screen mammalian cell expressed libraries of BG505
related gp140/gp120 molecules has identified a number of stabilized HIV Env trimers that bind to
both germline and mature bnAb versions [99]. Furthermore, several key studies have detailed that
structural and/or glycan heterogeneity, localized precursor frequency, and BCR affinity each have an
interdependent role to play in the stimulation and expansion of bnAb precursors [100,101]. This work
is highly likely to lead to a clearer definition of the key protein/glycan moieties that trigger the
initial antigen-specific B cell activation that leads to the fully mature bnAb capable of neutralizing the
virus, and it will be critical to move these designed Env, capable of stimulating precursor bnAbs and
promoting their continued maturation into high affinity viral neutralisers, as quickly as possible into
clinical trials.
5. Inferring from Transmitted Founder (T/F) Viruses to Guide HIV Vaccine Development
One of the major goals for HIV vaccine development is to prevent HIV-1 acquisition at mucosal
surfaces. Therefore, understanding the mucosal infection process is critical and is receiving much
attention. During sexual transmission of HIV-1, the donor exposes the recipient to a viral swarm
consisting of billions of copies of genetically diverse virus. In the vast majority of cases (60–80%
of infections), a single virus successfully evades mucosal secretions in the mucosal vault, crosses
the mucosal epithelium, binds to and infects a susceptible target cell, avoids immune mediated
clearance, and goes on to establish a systemic infection. The fact that a single virus successfully
overcomes these host-obstacles out of the billions of virions the recipient is exposed to suggests this is
a relatively inefficient process. As such, questions surrounding the success of transmitted/founder
(T/F) viruses are being asked. Is this just a stochastic event where every virus has an equal opportunity
to establish infection, or are there phenotypic properties associated with T/Fs that predispose them
towards successful infection? It is important to understand that nature has provided us with the
necessary proof of concept that bnAbs responses can be generated in humans and that autologous
neutralizing antibody responses are precursors to the bnAb response. Therefore, the T/F Envs and
related breakthrough viruses may provide essential insights into novel vaccine strategies and improved
immunogen design.
In a study involving heterosexual transmission pairs from largely monogamous cohabitating
couples in Zambia, Derdeyn et al. evaluated the nature of heterosexually transmitted HIV-1 infection
in a bid to better understand the infecting virus. In seven transmission pairs, the transmitted virus
clustered with subtype C reference strains, and in one transmission pair, infecting virus clustered with
subtype G [102]. They evaluated a 257 nucleotide sequence stretch spanning positions 391–1254 of
the HIV Env (HXB2 numbering) coding region and then focused only on sequences that spanned the
V1–V4 region. By comparing the frequency of sequences below at or above the median donor length,
recipients from 6 of the 8 pairs had V1–V4 lengths that were below the donor median [102], suggesting
that viruses encoding Env glycoproteins with shorter V1–V4 regions may be transmitted more easily
or are fitter in recipients. Further analysis revealed the transmitted virus in 5 of the 8 pairs contained
a statistically significant lower number of potential N-linked glycan (PNLG) sites than the median
number in the corresponding donor [102], thereby providing tantalizing evidence that T/F viruses
may indeed express certain phenotypic characteristics that distinguishes them from the rest of the
inoculating viral swarm. A subsequent study in Kenya evaluated the viral Env V1–V2 length and
looked for evidence of reduced N-linked glycosylation in viruses samples from 27 women and eight
men within 70 days of heterosexually acquired infection [103]. Again, the subtype A sequences from
early infection were found to have significantly shorter V1–V2 loop sequences and fewer potential
N-linked glycosylation (PNLG) sites [103], collectively strengthening support for shorter hypervariable
regions, with fewer PNLG sites being important for T/F viruses. Conversely, in the later study, the T/F
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viruses from a cohort of 13 men and women infected with subtype B HIV-1, within 142 days post
seroconversion, did not show evidence of having shorter V1–V2 sequences than those found in the
Los Alamos database. Furthermore, they did not find any reduction in the number of potential PNLG
sites, indicating that shorter hypervariable regions and fewer N-linked glycan might not play a role in
mediating HIV transmission in subtype B infection [103].
Most HIV-infected patients develop neutralizing antibody responses (nAb) against the autologous
infecting strain early in infection. However, this nAb response displays no cross-strain neutralizing
activity. To better understand how T/F viruses can generate neutralizing antibody responses, Li et al.
evaluated the course and magnitude of the nAb response against Env glycoproteins present at acute
and early infection with subtypes B and C HIV-1 [104]. While the course of nAb responses in plasma
were similar between the two cohorts, subtype C infected individuals developed plasma nAb responses
that were 3.5-fold higher than those seen in subtype B-infected individuals [104]. Critically, the higher
titres in the subtype C cohort were associated with viruses having significantly shorter V1–V4 amino
acid lengths with fewer glycosylation sites than the B cohort [104]. The fact that subtype C virus
triggered autologous nAbs and that the T/F virus had shorter and less glycosylated Envs suggests this
phenotype could be exploited for rationale vaccine design. However, for an efficacious clade C vaccine
to be realized, increasing the neutralizing breadth of the nAb response would be necessary.
The HIV Env spike is a metastable complex composed of surface gp120 subunits noncovalently
linked to gp41 transmembrane domains. The trimerization of the Env complex are the result
of noncovalent interaction between the gp41 subunits with additional interactions arising from
gp120-gp120 contacts near the trimers apex [105]. The Env oligomers function is to facilitate target
cell binding and entry by engaging CD4 and the coreceptor CCR5. As with other viruses, surface Env
density plays an important role in mediating cell fusion. However, HIV is set apart from most viruses in
that there is a relative sparsity of intact Env trimers displayed on the viral surface (~7–14 spikes/virion),
and spontaneous shedding of Env oligomers is known to occur. As such, HIV displays far fewer
Env than other viruses such as SIV (~70 spikes/virion), Influenza (~300 spikes/virion), Adenovirus
(240 hexon trimers/virion), and Hepatitis B Virus (~120 spikes/virion) [106]. The precise numbers of
intact surface Envs necessary to mediate target cell infection is not known, but various reports range
from 1–8 trimers [107–110]. Therefore, it is important to note that T/F viruses have been described
to display a greater Env density than viruses analyzed at later timepoints in infection. A study by
Gnanakaran et al. searched for amino acid signatures in subtype B Env sequences that were associated
with transmission and sequences that were recurring in chronic infection [111]. By assessing thousands
of sequences from hundreds of patients, a number of signatures were identified as promising. The
first was located at position 12 in the Env signal peptide (SP), and the second was the loss of an
N-linked glycosylation site at position 413–415 [111]. Both signatures were described to potentially
influence Env expression and incorporation into virions. The Env SP is fairly long (~30 amino acids)
and contains a polar N-terminus followed by a hydrophobic core. The role of the SP is directing Env
in its translocation to the endoplasmic reticulum (ER), where it undergoes, folding, glycosylation,
and trimerization. When compared to the cleavage of the SP of other glycoproteins, the cleavage
of the HIV SP is slow [112,113]. Therefore, a histadine (H) at position 12, despite being present in
both early and chronic viruses, was found to be statistically significantly enriched in early viruses
compared to chronic viruses, which in the latter case was commonly mutated to arginine (R) or proline
(P). As for loss of a probably N-linked glycosylation site (PNLG) at position 413–415, a mutation
away from 415Threonine (T) was found to be enriched within acute samples or early after infection.
The 415T is part of the PNLG sequon at N413 and is normally glycosylated [111]. This is near the
c-terminal end of the V4 loop and proximal to the CCR5 coreceptor binding site and CD4 binding site.
Critically, PNLG at 413–415 correlates with reduced b12 binding [111]. This work was supported by a
computational approach described by Asmal et al., who showed that in T/F viruses, 415H or a similar
positive charged amino acid such as arginine (R), as opposed to non-basic residues at this locus, is
associated with higher Env expression and incorporation into virions [114], thereby further setting the
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stage for phenotypic differences in T/F viruses compared to chronic viruses. Interestingly, Parrish et al.
found that clade B and C T/F viruses contained 1.9 times more Env per unit of reverse transcriptase
(RT) activity than chronic viruses, and that T/F viruses were 1.7-fold more efficiently captured by
monocyte derived DC [115]. It could be speculated that higher Env density on T/F viruses may help
them to bind and infect both tissue resident and infiltrating CD4 T cells, thereby giving them a higher
chance of establishing infection. It is also plausible to assume that HIV modulates its glycan content
to evade immune responses and to also specifically target mucosal resident DCs for lectin-mediated
binding (e.g., DC-SIGN) and transport them to regional draining lymph nodes. Taken together,
although still a controversial topic, T/F viruses appear to have significant phenotypic properties
that could be exploited for the purposes of an efficacious HIV-1 vaccine. From an immunological
and vaccine point of view, understanding Env density and the glycan shield on the HIV virus is
critical, as it influences B cell activation through BCR cross linking and down-stream processes such
as clonal expansion and antibody affinity maturation, thereby giving potential insights into how
autologous neutralizing antibodies might be generated and what is special about the individuals
that generate broadly neutralizing antibody responses. In essence, studying the continual arms race
between infecting virus and the humoral immune response could illuminate antibody lineages and
their associated viral escape mutants that eventually allow specific Envs, amongst the circulating
quasi-species, to promote autologous and broadly neutralizing antibody production.
With that in mind, McCurly et al., constructed and tested T/F based vaccine constructs using
sequential clade C Envs from a south African Individual (CH0505) known to elicit CD4bs neutralizing
antibody in NHPs [116]. The CH0505 T/F Env, week 53, week 78, and week 100 Envs were presented
by virus like particles (VLPs) with or without co-administered gp120. It was speculated that the
conformation of the T/F Env would enable the correct angle of approach for engagement of B cells
targeting the CD4bs [116]. The outcome was neutralization of autologous tier 2 T/F virus, but the
vaccine had no breadth for other tier 2 viruses despite Abs being mapped to the CD4bs. This study
demonstrated that using sequential Env vaccinations could initiate a B cell lineage with potential to
evolve towards heterologous neutralization [116].
By studying viral-host coevolution over a 0–5 year period of a clade C infection, Bonsignori et al.
were able to identify key events in the ontogeny of V3 glycan bnAb response within a Malawian
individual CH848. Sequential sampling of the virus over this time revealed neutralization was
restricted to virus that contained an N332 N-linked glycosylation site [117]. In this instance, the length
of the V1 loop of the T/F virus was 34 residues, while the average V1 amino acid length in the Los
Alamos database was 28 residues. The viral quasi-species was then shown to undergo a transition from
a long V1 loop in the T/F to a short loop (~16–17 amino acids) when escaping from the autologous
neutralizing antibody response [117]. This truncated V1 loop caused the expansion of the DH270 bnAb
lineage, placing significant pressure on the virus, causing it to select for viral escape mutants with
longer V1 loops. This ultimately increased bnAb breadth by enabling DH270 to recognize a broader
spectrum of Envs. It is noteworthy that the DH270 unmutated common ancestor did not bind the T/F
Env but did bind to peptides from the base of the V3 loop [117]. Thus, vaccine priming with T/F virus
Env, V3 based structures, or peptide antigens from V3, followed by Envs with progressive longer V1
lengths, might induce V3-glycan bnAbs [117]. Indeed, changes to the V1/V2 length over the course of
HIV infection have previously been reported to increase along with the number of PNLG sites [118].
This latter example highlights that sequential vaccinations strategies with multiple Env modalities
might be necessary to harness the necessary B cell lineages that can lead to the generation of bnAbs.
In another study, vaccination of NHPs with a cocktail of gp140 oligomeric Envs from an HIV-1
T/F and 6 of its variants, all derived from an HIV-1 infected African (CAP206) who generated bnAbs
against the gp41 MPER region, was carried out [119]. In this study, potent neutralizing antibody titres
were generated against tier 1 viruses in all animals, while the vaccine also managed to produce a
neutralizing antibody lineage that had tier 2 neutralization in some animals [119]. The neutralization
profile resembled the plasma response seen at 6 months within the CAP206 individual but was shown
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to bind to the V5 region of Env, thereby demonstrating that T/F Env and variants can generate
autologous tier 2 neutralizing antibody [119].
Collectively, these observations indicate that the phenotypic properties of T/F viruses appear
sufficiently distinct from the rest of the viral swarm and that their Env glycoproteins could be important
for a protective vaccine. Future vaccine studies investigating sequential vaccination strategies, starting
with T/F Envs and finishing with accurately constructed Env trimers, might induce the necessary
B cell ontogenesis by immuno-focusing on the necessary structural components that culminate in
bnAb responses.
6. Ongoing Clinical and Preclinical Testing of HIV Vaccines
Viral vectors are the best delivery tools for vaccine development, because they have intrinsic
adjuvant capability and unique cellular tropism, and they are able to trigger robust adaptive immune
responses. A number of new vectors, including Ad26 (adenovirus serotype 26), Ad35, poxvirus
(e.g., canarypox virus-based ALVAC vector), replication competent Ad4, and CMV vectors, are
currently being developed (Table 2) [120–124]. However, viral vector vaccine platforms do have some
limitations, such as preexisting immunity. It is also noticed that different vectors, even derived from
phylogenetically similar viruses, can elicit substantially distinct immune responses, in terms of quality,
quantity, and location, which can ultimately affect protection efficacy. The two-viral vector-based
vaccine trials, Imbokodo and HVTN 702, have resulted from years of scientific testing and clinical
development, currently representing the best efforts in HIV vaccine development. Both HVTN 702
and Imbokodo trials are described in more detail below.
Table 2. Recent and ongoing HIV clinical trials.
Trial ID Vaccine Description Category Phase Duration
NCT01084343 Virosome (IRIV) expressing lipidatedgp41 peptide
Virosome
based I 2009.11–2010.09
RV305 ALVAC-HIV (vCP1521) and/or AIDSVAXgp120 B/E late boost RV144-related II 2012.04–2017.05
RV306 ALVAC-HIV (vCP1521) prime,ALVAC-HIV/AIDSVAX gp120 B/E boost RV144-related II 2013.09–2017.11
RV328 AIDSVAX gp120 B/E prime and boost RV144-related II 2014.07–2018.12
HVTN100
ALVAC-HIV (vCP2438) prime,
ALVAC-HIV (vCP2438)/bivalent clade C
gp120/MF59 boost
RV144-related I/II 2015.01–2017.01
HVTN702
ALVAC-HIV (vCP2438) prime,
ALVAC-HIV (vCP2438)/bivalent clade C
gp120/MF59 boost
RV144-related IIb/III 2016.10–2021.07
X001 CN54gp140 with GLA-AF Envimmunogens I 2013.10–2015.11
CR104488/HIV-V-A003/IPCAVD008 Trimeric gp140 with/withoutaluminum phosphate
Env
immunogens I 2014.12–2016.04
FLSC-001 Full length single chain gp120-CD4complex vaccine
Env
immunogens I 2015.11–2018.07
CR100965/HIV-V-A002/IPCAVD006 MVA Mosaic HIV in individualswith/without prior Ad26.ENVA.01
Mosaic
vaccine I 2014.09–2015.11
CR106152/HIV-V-A004/IPCAVD009
Ad26 Mosaic HIV prime, Ad26 Mosaic HIV
or MVA Mosaic (env or gag-pol) and/or
clade C gp140/aluminum phosphate boost
Mosaic
vaccine I/II 2014.12–2019.04
CR108152/VAC89220HPX2004
Ad26 Mosaic HIV or Ad26 Mosaic4 HIV
prime (env or gag-pol), clade C
gp140/aluminum phosphate and Ad26
Mosaic HIV or Ad26 Mosaic4 HIV boost
Mosaic
vaccine II 2016.07–2018.09
CR108068/VAC89220HPX1002
Ad26 Mosaic HIV (env or gag-pol) with
clade C gp140/aluminum phosphate prime
and boost
Mosaic
vaccine I 2016.03–2019.01
HVTN 090/NCT01438606 VSV-Indiana HIV gag vaccine Replicatingvectors I 2011.10–2013.01
NCT01989533 Ad4-mgag and Ad4-envC150 Replicatingvectors I 2013.11–2020.02
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Table 2. Cont.
Trial ID Vaccine Description Category Phase Duration
HVTN 110
Ad4-mgag and/or Ad4-envC150 prime,
AIDSVAX gp120 B/E/aluminum
hydroxide boost
Replicating
vectors I 2015.03–2017.02
rcAd001/IAVI R001 RcAd26.Mosaic1.HIV-env Replicatingvectors I 2015.01–2016.06
HVTN076/NCT00955006
VRC-HIVDNA-016-00-VP prime (clade B
gag, pol, nef, clade ABC env)
VRC-HIVADV014-00-VP boost (clade B
gag-pol and clade ABC env)
DNA-based I 2011.05–2013.09
HVTN 087
HIV-MAG vaccine with/without IL-12
pDNA adjuvant electroporation prime,
VSV HIV gag boost
DNA-based I 2012.05–2014.09
CRO2059
HIV DNA (CN54ENV/ZM6GPN) prime,
MVA-/CN54rgp140/GLA-AF
adjuvant boost
DNA based I 2014–2016
HVTN 092
DNA-HIV-PT123 prime with/without
NYVAC-HIV-PT1 and NYVAC-HIV-PT4
boost
DNA-based I 2013.04–2014.09
HIV-CORE 004/IAVI N004
Ad35-GRIN/MVA.HIVconsv with/without
pSG2. HIVconsv DNA with/without
electroporation
DNA-based I/II 2014.03–2015.08
HVTN 106 DNA Nat-B env or DNA CON-S env orDNA Mosaic env prime, MVA-CMDR boost DNA-based I 2015.01–2020.09
HVTN 098
PENNVAX®-GP HIV-1 DNA (gag, pol, env)
vaccine with electroporation with/without
IL-12 DNA adjuvant
DNA-based I 2015.04–2016.08
CUTHIVAC002 HIV DNA-C CN54env prime with andwithout electroporation, CN54gp140 boost DNA-based I 2015.11–2017.04
VRI01
LIPO-5 or MVA HIV-B LIPO-5 or MVA
HIV-B or GTU-Multi HIV B prime and
LIPO-5 or MVA HIV-B boost
Lipopeptides I/II 2014.03–2016.03
Some of the current ongoing and recently completed human clinical trials are shown. Note: This is not a complete
list. Ad = Adenovirus; CN = Chinese; CUTHIVAC = Cutaneous and Mucosal HIV Vaccination; Env = viral
envelope; FLSC = full-length single chain; GLA-AF = glucopyranosyl lipid adjuvant–aqueous formulation; GP
= glycoprotein; HVTN = HIV Vaccine Trials Network; IAVI = International AIDS Vaccine Initiative; IPCAVD =
Integrated Preclinical/Clinical AIDS Vaccine Development Program; MVA = modified vaccinia virus Ankara; NCT
= National Clinical Trials identifier; vCP = canarypox vector; VRC = Vaccine Research Centre (USA); VRI = Vaccine
Research Institute.
6.1. HVTN702
The HVTN 702 study is a Phase 2b/3 clinical trial based on the modestly protective RV144 clinical
trial [78,125]. The vaccine regimen consists of two experimental vaccines: a canarypox-vector based
vaccine called ALVAC-HIV and a two-component gp120 protein subunit. Based on the vaccines used
in RV144, both ALVAC-HIV and the protein subunit have been modified to be HIV subtype C-specific.
In addition, MF59 (an adjuvant different from the one used in RV144) was combined with the protein
component in order to elicit a more robust immune response. Finally, the participants will receive
booster shots at the one-year mark in the hope of prolonging the early protective effect observed
in RV144.
The HVTN 702 study is the most advanced and largest HIV vaccine clinical trial initiated thus far
and will be carried out in South Africa. It will enroll 5400 healthy, sexually active men and women
aged 18 to 35 years old. Half of the participants will be randomly assigned to receive the experimental
HIV vaccine regimen, and the other half will receive a placebo. A total of five injections will be given
to participants over one year and then will be followed up for another two years. Results from the
study are expected in late 2020.
6.2. Imbokodo Efficacy Trials
Imbokodo is a Phase 2b proof-of-concept study, and the vaccine regimen is based on “mosaic”
immunogens in an effort to induce immune responses targeting the diverse global HIV strains, which
differs from HVTN 702 study. Prior studies in NHP with these mosaic-based vaccines were able
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to protect monkeys from SHIV challenge [126]. Furthermore, two early-stage human clinical trials,
APPROACH and TRAVERSE, showed that these vaccines are well-tolerated and can generate HIV
specific immune responses in the vaccinees. Based on the findings from these two early-stage clinical
trials, a lead candidate regimen was selected for further evaluation [127].
The APPROACH study was a phase I/II clinical trial initiated in Dec. 2014 and was scheduled
for completion in April 2019 [128]. It enrolled 400 participants (18–50 years). The purpose of this
study is to evaluate the safety/tolerability of different regimens containing Ad26.Mos.HIV, Modified
Vaccinia Ankara (MVA)-Mosaic, and/or HIV-1 Clade C gp140 drug product (gp140 DP) components
through intramuscular route and to compare Env specific antibody responses between the different
vaccine regimens.
The TRAVERSE study is a double-blind clinical trial phase I/II started in Jun. 2016 and completed
in May 2018 [129]. It enrolled 198 participants (18–50 years) in the United States and Rwanda.
The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens;
it first aims to prime with trivalent Ad26.Mos.HIV and boost with trivalent Ad26.Mos.HIV and Clade
C gp140 plus adjuvant; secondly, it aims to prime with tetravalent Ad26.Mos4.HIV and boost with
Ad26.Mos4.HIV and Clade C gp140 plus adjuvant. Interim data indicate that both are well-tolerated
and can elicit anti-HIV immune responses [127].
The Imbokodo trial is to evaluate the quadrivalent mosaic vaccine based on the TRAVERSE
study. It will enroll 2600 HIV-negative women in sub-Saharan Africa. All participants will receive four
vaccinations of either the experimental vaccine regimen or placebo over one year. The final two doses
will be given together with an HIV clade C gp140 protein and an adjuvant (aluminum phosphate).
Participants will be followed up over two years. Results from Imbokodo are expected in 2021.
The ASCENT trial is another ongoing adenovirus vector-based HIV mosaic vaccine trial. It is a
double-blind phase I/II clinical trial initiated in Mar. 2017. It enrolled 150 participants (18–50 years).
The primary purpose of the study is to assess safety/tolerability and Env-specific antibody responses
of two different mosaic-based vaccine regimens, i.e., Ad26.Mos4.HIV vaccine through intramuscular
route at Week 0 and 12, followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine
containing 250 mcg (microgram) of total protein mixed with adjuvant (aluminium phosphate) at Week
24 and 48, or Ad26.Mos4. HIV vaccine at Week 0 and 12 followed by Ad26.Mos4.HIV vaccine and a
combination of 125 mcg Mosaic gp140 and 125 mcg Clade C gp140. Results from ASCENT are expected
in early 2019 [130].
7. Application of Systems Biology and Serology for Improved Vaccines
Systems serology approach offers an unbiased and comprehensive approach to systematically
survey humoral immune responses, capturing the array of functions and humoral response
characteristics that may be induced following vaccination with high resolution. Coupled to machine
learning tools, large datasets that explore the “antibody-ome” can help in the identification
of features associated with humoral immunity that distinguish protective from non-protective
responses [131]. Systems serology is able to associate antibody features and functions with protection
from HIV infection, which is now becoming a powerful tool with which to investigate the humoral
immune system.
A number of different data-driven computational approaches or “machine learning” have been
applied to systems biology, systems vaccinology [132,133], and, more recently, systems serology [134].
These applications have identified correlations between certain immune signatures and vaccine
efficacy for a number of diseases such as yellow fever [135], influenza [136], and malaria [137,138].
Chung, et al. utilized a variety of modelling and data clustering techniques to outline the antibody
profiles of two non-efficacious HIV vaccine trials: VAX003 (AIDSVAX B/E [67]) and HVTN204
(DNA/rAD5 [139]) [140], and the moderately protective RV144 trial (ALVAC and AIDSVAX B/E [78]).
Application of correlation networks analysis to these different vaccine trials revealed that, in RV144
trial, Env-specific IgG1 and IgG3 responses were correlated with multiple antibody effector functions,
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such as ADCC, ADCP, and ADCDC. On the contrary, these correlations were not found in the two
non-efficacious vaccine trials. Furthermore, they used the immune correlate analysis to separate
RV144 recipients into two groups with either high or low V1/V2 responses [141]. As expected,
the former, with predicted low risk of infection, had high HIV-specific IgG1 levels and polyfunctional
Fc effector functions including ADCP, ADCC, and antibody-dependent NK cell activation. On the
other hand, the low IgG V1/V2 responders, with predicted higher risk of infection, were correlated
with HIV-specific IgA, which is consistent with previous immune correlate studies [141]. This includes
the analysis of risk of infection by Tomaras et al. that revealed plasma IgA/IgG ratios were higher in
infected individuals than in uninfected vaccine recipients and that Env-specific IgA antibodies from
RV144 vaccinees could block binding of ADCC-mediating mAb to HIV-1 gp120 [142]. Further analysis
showed that the high IgG3-V1/V2 responders were associated with activating FcγRIIa and FcγRIIIa,
receptors required for ADCP and critical for NK cell activation and ADCC, respectively, which was also
confirmed to be associated with protection by other studies [143]. Although IgA has been correlated
with lack of protection in RV144, it is important to note that other studies have identified protective
effects of vaccine-elicited anti-HIV IgA [144]. Therefore, it is worth mentioning that a phase I, double
blinded study published by Leroux-Roels et al. and conducted in 24 healthy HIV-uninfected women
demonstrated the safety, tolerability, and immunogenicity of a virosomal vaccine expressing HIV-1
gp41-derived P1 lipidated peptides (MYM-V101) [144]. In this study, vaginal and rectal P1-specific IgG
was induced, and in ~50% of the participants vaginal anti-P1 IgA was elicited. Although the induced
vaginal IgA was non-neutralizing, it was shown to inhibit HIV-1 transcytosis, thereby providing
evidence that anti-HIV IgA responses may be protective against HIV transmission. Taken together, the
systems serology and related bioinformatics analyses provided an ideal tool with which to study the
network for Fc functions and their pathway analyses [145,146].
Systems serology approaches in non-human primate (NHP) models and efficacy trials: Several
SIV and SHIV vaccine trials have also adopted systems serology approaches to analyze the vaccine
efficacy [147–149]. One example is an NHP study with an RV144-like vaccine consisting of an ALVAC
prime-followed by gp120 protein boost vaccine strategy. This study was analyzed by a combination
of systems biology and systems serology, which revealed the association of RAS activation, mucosal
IL-17-producing innate lymphoid cells, and V2 antibodies with delayed acquisition of infection [149].
In another NHP vaccine study, an Ad26 prime and Env protein boost resulted in 50% protection
efficacy from repeated SIV challenges. The systems serology analysis revealed that this protection was
associated with polyfunctional Fc effector functions including ADCP, ADCC, and ADCD, as well as
antibody-mediated NK cell activation [147].
The systems serology is still in its early developmental stages, and there is no doubt that it will
be further improved to better characterize comprehensive humoral immune responses. However,
by using systems serology, we have already been able to dissect the humoral immune responses in NHP
vaccine trials which provide us with a unique opportunity to understand the vaccine-elicited immune
responses to a much deeper degree. These approaches will eventually enable us to build parallels
between NHP and human protective responses, and help us design better vaccines for human trials.
8. Summary
Although over 35 years have passed since the discovery that HIV-1 was the etiological agent
behind the AIDS epidemic, a preventative vaccine has not yet been realized. During that time,
significant conceptual and technological advances have been made in HIV vaccinology, resulting
in efficacy studies of candidate vaccines that aimed to reduce the likelihood of HIV acquisition or
to increase the immune pressure on the virus and its escape mutants. Collectively, these studies
have provided critical insights into the potential correlates of protection that have been missing for
decades. HIV-1 is a highly mutable virus owing, in part, to its rapid replication and low fidelity reverse
transcriptase activity. From a historical standpoint, vaccinology has been successful at preventing
infections from organisms that express stable/invariant antigenic structures that can be targeted
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by antibodies. For this reason, the HIV-1 virus has essentially presented vaccine researchers with
a “moving target” for which to create a vaccine, necessitating the development of novel vaccine
approaches. It is important to understand that, despite the history of failures in HIV vaccine
development, the preclinical and early phase clinical vaccine pipeline is rich in both novel and
diverse anti-HIV vaccine strategies. This, coupled with the on-going efficacy trials designed to improve
upon RV144, leads many to see a bright future for HIV vaccine development.
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